ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C.


Journal Article

Chronic infection with the hepatitis C virus (HCV) affects 170 million people worldwide and is an important cause of liver-related morbidity and mortality. The standard of care therapy combines pegylated interferon (pegIFN) alpha and ribavirin (RBV), and is associated with a range of treatment-limiting adverse effects. One of the most important of these is RBV-induced haemolytic anaemia, which affects most patients and is severe enough to require dose modification in up to 15% of patients. Here we show that genetic variants leading to inosine triphosphatase deficiency, a condition not thought to be clinically important, protect against haemolytic anaemia in hepatitis-C-infected patients receiving RBV.

Full Text

Duke Authors

Cited Authors

  • Fellay, J; Thompson, AJ; Ge, D; Gumbs, CE; Urban, TJ; Shianna, KV; Little, LD; Qiu, P; Bertelsen, AH; Watson, M; Warner, A; Muir, AJ; Brass, C; Albrecht, J; Sulkowski, M; McHutchison, JG; Goldstein, DB

Published Date

  • March 18, 2010

Published In

Volume / Issue

  • 464 / 7287

Start / End Page

  • 405 - 408

PubMed ID

  • 20173735

Pubmed Central ID

  • 20173735

Electronic International Standard Serial Number (EISSN)

  • 1476-4687

Digital Object Identifier (DOI)

  • 10.1038/nature08825


  • eng

Conference Location

  • England